Fundz

Kezar Life Sciences, Inc. reported raising $28.4 Million in an initial SEC Form D filing, from an offering of $28.4 Million

TAKEN PRIVATEJun 22, 2015

Amount Raised

$28.4 Million

$28.4 Million sold, per SEC Form D (first sale Jun 22, 2015)

Round Type

Venture

CaliforniaBiotechnologyHealth CareTherapeuticsBiopharma

Quick answer

Kezar Life Sciences raised $28.4 Million in a funding round, dated June 22, 2015. Kezar Life Sciences is based in California, United States.

How much did Kezar Life Sciences raise?
Kezar Life Sciences raised $28.4 Million in a funding round on June 22, 2015.
What does Kezar Life Sciences do?
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders.
Where is Kezar Life Sciences based and how big is it?
Kezar Life Sciences is based in California, United States. Fundz records about 55 employees.
Who are the decision-makers at Kezar Life Sciences?
Fundz holds 1 contact at Kezar Life Sciences. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biopharma around the same time

Companies in the same sectors as Kezar Life Sciences that raised within 45 days of this round, from Fundz verified event records.

  • VistaGen raised $1.9M on August 6, 2015.
  • Protagonist Therapeutics, Inc raised $17M on July 24, 2015.
  • BioAtla raised $39M on July 21, 2015.
  • CUREMARK LLC raised $20M on July 13, 2015.
  • Monopar Therapeutics raised $2.1M (Seed) on June 18, 2015.
  • Milestone Pharmaceuticals raised $3.8M (Seed) on June 16, 2015.

Who to call at Kezar Life Sciences, and when

A new round usually means Kezar Life Sciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kezar Life Sciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kezar Life Sciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kezar Life Sciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kezar Life Sciences

Location

California, United States

About

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label, dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kezar Life Sciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Kezar Life Sciences's next move

See what Strategic adds

Kezar Life Sciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.